These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22863610)

  • 1. Mechanism of drug efficacy within the EGF receptor revealed by microsecond molecular dynamics simulation.
    Wan S; Wright DW; Coveney PV
    Mol Cancer Ther; 2012 Nov; 11(11):2394-400. PubMed ID: 22863610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
    Wang DD; Ma L; Wong MP; Lee VH; Yan H
    PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants.
    Saldaña-Rivera L; Bello M; Méndez-Luna D
    J Biomol Struct Dyn; 2019 Oct; 37(17):4671-4684. PubMed ID: 30558477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
    Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
    Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations.
    Songtawee N; Gleeson MP; Choowongkomon K
    J Mol Model; 2013 Feb; 19(2):497-509. PubMed ID: 22955422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
    Zou B; Lee VHF; Yan H
    BMC Bioinformatics; 2018 Mar; 19(1):88. PubMed ID: 29514601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations.
    Liu B; Bernard B; Wu JH
    Proteins; 2006 Nov; 65(2):331-46. PubMed ID: 16927343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
    Günther M; Lategahn J; Juchum M; Döring E; Keul M; Engel J; Tumbrink HL; Rauh D; Laufer S
    J Med Chem; 2017 Jul; 60(13):5613-5637. PubMed ID: 28603991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of quinoxalin-2(1H)-one derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Han X; Hu L; Li Z; Geng Z; Wang Z; Zeng C; Xiao X
    Anticancer Agents Med Chem; 2015; 15(2):267-73. PubMed ID: 25175686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.
    Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
    Biochem J; 2006 Aug; 397(3):537-43. PubMed ID: 16623663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
    Ding X; Liu X; Song X; Yao J
    Mol Inform; 2016 Oct; 35(10):529-537. PubMed ID: 27643705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor.
    Varkondi E; Pinter F; Robert K; Schwab R; Breza N; Orfi L; Keri G; Petak I
    J Recept Signal Transduct Res; 2008; 28(3):295-306. PubMed ID: 18569529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
    Yun CH; Boggon TJ; Li Y; Woo MS; Greulich H; Meyerson M; Eck MJ
    Cancer Cell; 2007 Mar; 11(3):217-27. PubMed ID: 17349580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines.
    Augustin A; Lamerz J; Meistermann H; Golling S; Scheiblich S; Hermann JC; Duchateau-Nguyen G; Tzouros M; Avila DW; Langen H; Essioux L; Klughammer B
    Mol Cancer Ther; 2013 Apr; 12(4):520-9. PubMed ID: 23371860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.
    Tamirat MZ; Koivu M; Elenius K; Johnson MS
    PLoS One; 2019; 14(9):e0222814. PubMed ID: 31536605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
    Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
    Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.